Novo Holdings A/S
In its 13F for Q1 2025 (holdings as of March 31, 2025, filed May 15, 2025), Novo Holdings A/S reported 31 stock positions worth $1.3 billion. Its top holding was VG Morningstar TS MKT ETF-US (VTI) at 21.7% of the portfolio, followed by Brookfield (BN, 9.3%) and Edgewise Therapeutics (EWTX, 9.0%). Compared with Q4 2024, it sold out of 3, added to 13 and reduced 4. The biggest buy was Edgewise Therapeutics (EWTX, shares +7%) and the biggest sale an exit from Tempus AI Class A (TEM).
- Most Recent 13F
- Q2 2026
- Location
- HELLERUP, G7
- CIK
- 0001388325
- Portfolio Value
- $1.3B (Q1 2025)
- SEC Filing
- 0000950123-25-005753 ↗ filed May 15, 2025
Holdings Value
Holdings 31 stocks · $1.3B
| VTI VG Morningstar TS MKT ETF-US | 21.71% | 1,038,550 | $285.4M | No change |
| BN Brookfield Corp. | 9.29% | 2,330,830 | $122.2M | Reduce -16.7% |
| EWTX Edgewise Therapeutics Inc. | 8.95% | 5,350,000 | $117.7M | Add +7.0% |
| ASML ASML Holding NV-NY Reg SHS | 8.36% | 165,836 | $109.9M | No change |
| CRM Salesforce Inc. | 5.57% | 272,801 | $73.2M | Reduce -7.2% |
| MIRM Mirum Pharmaceuticals Inc. | 5.14% | 1,500,000 | $67.6M | No change |
| INSM Insmed Inc. | 4.21% | 724,666 | $55.3M | No change |
| RXRX Recursion Pharmaceuticals-A | 3.89% | 9,665,128 | $51.1M | Reduce -4.4% |
| BABA Alibaba Group Holding-SP ADR | 3.75% | 372,327 | $49.2M | Reduce -17.7% |
| CRNX Crinetics Pharmaceuticals Inc. | 3.25% | 1,275,000 | $42.8M | Add +32.8% |
| BMRN Biomarin Pharmaceutical Inc. | 2.63% | 490,000 | $34.6M | No change |
| AVBP Arrivent Biopharma Inc. | 2.63% | 1,872,142 | $34.6M | Add +23.1% |
| PCVX Vaxcyte Inc. | 2.63% | 915,000 | $34.6M | Add +22.0% |
| MRUS Merus NV | 2.53% | 789,129 | $33.2M | Add +5.2% |
| VRDN Viridian Therapeutics Inc. | 2.31% | 2,250,300 | $30.3M | Add +0.0% |
| PHVS Pharvaris NV | 2.06% | 1,725,000 | $27.1M | No change |
| FOLD Amicus Therapeutics Inc. | 1.71% | 2,750,000 | $22.4M | Add +10.0% |
| CLDX Celldex Therapeutics Inc. | 1.66% | 1,200,000 | $21.8M | Add +20.0% |
| BPMC Blueprint Medicines Corp. | 1.54% | 228,804 | $20.3M | Add +30.8% |
| ZBIO Zenas Biopharma Inc. | 1.33% | 2,214,967 | $17.5M | Add +38.4% |
| CBLL Ceribell Inc. | 1.29% | 880,000 | $16.9M | Add +167.6% |
| VERV Verve Therapeutics Inc. | 1.04% | 3,000,000 | $13.7M | Add +25.0% |
| RCKT Rocket Pharmaceuticals Inc. | 0.56% | 1,100,000 | $7.3M | No change |
| FDMT 4D Molecular Therapeutics Inc. | 0.48% | 1,950,000 | $6.3M | Add +30.0% |
| LXEO Lexeo Therapeutics Inc. | 0.30% | 1,122,581 | $3.9M | No change |
| LANZATECH GLOBAL INC | 0.29% | 15,814,845 | $3.8M | No change |
| IOBTQ Io Biotech Inc. | 0.28% | 3,354,449 | $3.7M | No change |
| KYTX Kyverna Therapeutics Inc. | 0.27% | 1,850,000 | $3.6M | No change |
| ABCL Abcellera Biologics Inc. | 0.19% | 1,126,915 | $2.5M | No change |
| MQ Marqeta Inc. | 0.14% | 441,558 | $1.8M | No change |
| DMRA Damora Therapeutics Inc. filed as GALECTO INC | 0.02% | 99,913 | $310K | No change |
Portfolio Sells Q4 2024 → Q1 2025
| TEM Tempus AI Inc. Class A | Sold out | 0.00% | −8.33 |
| CRGX Cargo Therapeutics Inc. | Sold out | 0.00% | −1.45 |
| BN Brookfield Corp. | Reduce -16.7% | 9.29% | −0.44 |
| CRM Salesforce Inc. | Reduce -7.2% | 5.57% | −0.38 |
| MERSANA THERAPEUTICS INC | Sold out | 0.00% | −0.37 |
| RXRX Recursion Pharmaceuticals-A | Reduce -4.4% | 3.89% | −0.25 |
| BABA Alibaba Group Holding-SP ADR | Reduce -17.7% | 3.75% | +1.42 |
Portfolio Buys Q4 2024 → Q1 2025
| EWTX Edgewise Therapeutics Inc. | Add +7.0% | 8.95% | +0.87 |
| CBLL Ceribell Inc. | Add +167.6% | 1.29% | +0.77 |
| MRUS Merus NV | Add +5.2% | 2.53% | +0.62 |
| BPMC Blueprint Medicines Corp. | Add +30.8% | 1.54% | +0.62 |
| ZBIO Zenas Biopharma Inc. | Add +38.4% | 1.33% | +0.54 |
| FOLD Amicus Therapeutics Inc. | Add +10.0% | 1.71% | +0.28 |
| CRNX Crinetics Pharmaceuticals Inc. | Add +32.8% | 3.25% | +0.28 |
| VERV Verve Therapeutics Inc. | Add +25.0% | 1.04% | +0.22 |
| AVBP Arrivent Biopharma Inc. | Add +23.1% | 2.63% | +0.18 |
| CLDX Celldex Therapeutics Inc. | Add +20.0% | 1.66% | +0.13 |
| FDMT 4D Molecular Therapeutics Inc. | Add +30.0% | 0.48% | −0.03 |
| VRDN Viridian Therapeutics Inc. | Add +0.0% | 2.31% | −0.30 |
| PCVX Vaxcyte Inc. | Add +22.0% | 2.63% | −1.09 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 25 | $1.7B | EWTX, ASML, COAG, BN, MPLT |
| Q1 2026 | 22 | $1.2B | EWTX, BN, ASML, MIRM, MPLT |
| Q4 2025 | 24 | $1.3B | BN, EWTX, ASML, MIRM, CRM |
| Q3 2025 | 27 | $1.6B | VTI, BN, ASML, MIRM, EWTX |
| Q2 2025 | 29 | $1.4B | VTI, BN, ASML, CRM, MIRM |
| Q1 2025 | 31 | $1.3B | VTI, BN, EWTX, ASML, CRM |
| Q4 2024 | 34 | $1.7B | VTI, BN, TEM, EWTX, ASML |
| Q3 2024 | 37 | $2.0B | VTI, TEM, BN, EWTX, CORT |
| Q2 2024Amended | 38 | $1.9B | VTI, BN, TEM, ASML, CRM |
| Q1 2024 | 35 | $1.4B | ASML, BN, CRM, EPC, CORT |